

## New case report with Ozilia published: "Effective for both pain relief and reduced frequency of migraine attacks"

**A new Italian scientific case report, from a team at Campus Bio-Medico in Rome, detailing the Chordate treatment method Ozilia, reports on a 60-year-old male patient whose days with migraines decreased significantly, from 18 to 7 days per month, with a simultaneous significant reduction in pain level. The case report was recently published in the prestigious scientific journal Cephalalgia Reports.**

"This is another example of a patient who does not respond to, or no longer receives benefit from, common medications for chronic migraines, but where Ozilia treatment appears to have worked well," says Anders Weilandt, CEO of Chordate. Weilandt adds that it should be noted that this does not refer to the expected publication of Chordate's significant migraine study PM007.

The report indicates that pain relief and reduction of migraine days from the initial treatment period had a sustained effect. After about three months, the patient underwent another treatment period with Ozilia, resulting in a quicker and more significant response:

"The preliminary results confirm that KOS treatment is effective both in relieving acute pain and reducing attack frequency. Although the precise mechanism by which KOS modulates the trigeminal-autonomic reflex is still speculative, it could be a viable alternative to the treatment of resistant and refractory chronic migraine, when other approved treatments have been shown to be ineffective or poorly tolerated," the authors write in the conclusion of the report.

The report, [\*Extended regular use of kinetic oscillation stimulation \(KOS\) in refractory chronic migraine: case report of a first, single-subject experience\*](#), was authored by a group of doctors and researchers under the leadership of Professor Fabrizio Vernieri, Director of Headache and Neurosonology at Bio-Medico Campus University Hospital in Rome.

[Read the full report](#)

**For more information, please contact:**

Anders Weilandt, CEO

[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)

Cell: +46 733-874277

### **About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

### **Attachments**

[New case report with Ozilia published: "Effective for both pain relief and reduced frequency of migraine attacks"](#)